Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
|Articles|December 2, 2021
Pharmacy Clinical Pearl of the Day: Churg-Strauss Syndrome
Author(s)Saro Arakelians, PharmD
Churg-Strauss syndrome causes inflammation that can restrict blood flow to organs and tissues.
Advertisement
Clinical Pearl of the Day: Churg-Strauss Syndrome
Churg-Strauss syndrome is a disorder marked by blood vessel inflammation.
Insight:
- This inflammation can restrict blood flow to organs and tissues, sometimes permanently damaging them.
- This condition is also known as eosinophilic granulomatosis with polyangiitis (EGPA).
- Adult-onset asthma is the most common sign of Churg-Strauss syndrome.
- Symptoms may include loss of appetite, weight loss, joint and muscle pain, abdominal pain, weakness, fatigue, rash, skin sores, pain, numbness and tingling in the hands and feet.
- Complications may include peripheral nerve damage, heart disease, and kidney damage.
- Diagnosis may include blood test, imaging tests, and biopsy of the affected tissue.
- Treatment may include corticosteroids, such as Prednisone, to reduce inflammation; Mepolizumab (Nucala); and other medications such as azathioprine (Azasan, Imuran), benralizumab (Fasenra), cyclophosphamide, methotrexate (Trexall), and rituximab (Rituxan).
Sources:
Advertisement
Related to this article
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
5